Dr. Hege is responsible for advancing a pipeline of small molecules, biologics and cell therapies from first-in-human studies through clinical proof-of-concept and she led the bluebird-partnered BCMA CART cell program (Abecma) in multiple myeloma from inception through FDA approval. Prior to BMS she held a similar role at Celgene as well as executive roles in biotech at Cell Genesys, Cellerant, and Theraclone.
In addition, Dr. Hege is a Clinical Professor at UCSF where she sees patients with blood cancers weekly. She also serves on the Board of Directors of Mersana Therapeutics and Graphite Bio and served on the Board of the Society for Immunotherapy of Cancer for a 3-year term from 2016-2019.
Dr. Hege received her M.D. at UCSF and internal medicine and hematology/oncology subspecialty training at Harvard and UCSF, respectively. She was recognized by Fierce Biotech as one of the top 12 women in Biopharma in 2015, by the Healthcare Businesswomen’s Association as a “Luminary” in 2019, by San Francisco Business Times as one of the most influential women in Bay Area business in 2021 and most recently as a PharmVOICE100 honoree. Her career path and long history with CAR T cell development was featured during the 25th anniversary celebration of Nature Medicine.